Trends in overall survival in 133 cases of balloon cell melanoma: An NCDB analysis.

Authors

null

Xinxin Wu

Creighton University School of Medicine, Omaha, NE

Xinxin Wu , Darby Keirns , Beau Hsia , Peter T. Silberstein

Organizations

Creighton University School of Medicine, Omaha, NE, Creighton University School of Medicine (Phoenix Regional Campus), Phoenix, AZ, Creighton University, Omaha, NE

Research Funding

No funding received
None.

Background: Balloon cell melanoma (BCM) is a rare, malignant subtype of melanoma characterized by large, foamy melanocytes lacking pigmentation with a low overall 5-year survival rate of 37.5%. The incidence of melanoma is increasing at a greater rate than other types of cancer, but the cases of this subtype remain low. Demographic factors were analyzed via the National Cancer Database (NCDB) in an attempt to mitigate the knowledge gap in BCM diagnoses. The primary site at presentation and the effects of demographic factors on overall survival are described. Methods: A retrospective cohort analysis utilizing the NCDB from 2004 to 2020 included patients diagnosed with histologically confirmed BCM (N = 133). Socio-demographic factors (sex, age at diagnosis, race, facility type, and insurance type) were analyzed for frequency. A multivariate analysis of factors was performed on overall survival via the Kaplan–Meier Method (p = 0.05). Results: Since 2004, the number of cases diagnosed with BCM has steadily decreased (R2 = 0.204). The average age at diagnosis was 58.17 years (SD = 17.3). Most patients were male (63.9%), White (94.0%), treated at a non-academic center (56.4%), and had government insurance (96.1%). On multivariate analysis, age, race, and insurance type had statically significant effects on overall survival (p < 0.001). Patients that were older at diagnosis had poorer overall survival (p < 0.001, CI = [1.022 - 1.075]). Black patients were 4.6 times more likely than White patients to have suffered death (p < 0.001, CI = [23.586 - 450.230]). Patients without insurance were more likely to die than patients with government insurance (p < 0.001, CI = [0.026 - 0.229]). The average time from diagnosis until death was 143.1 months (SD = 8.0) with a 1-year and 5-year survival rate of 92.0% and 72.2%, respectively. Conclusions: This is the first study analyzing trends and demographic features relating to BCM in the NCDB. Due to the low survival rate of this cancer, understanding the risk factors affecting overall survival serve as a valuable clinical tool for prognostic evaluation. This database analysis suggests that the survival rate of BCM might be higher than previous literature suggests. The differences in BCM treatment on overall survival were not described in this study. Future research should aim to evaluate other prognostic factors, such as treatment, on survival.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e21508)

DOI

10.1200/JCO.2023.41.16_suppl.e21508

Abstract #

e21508

Abstract Disclosures